Skip to main content
Top
Published in: Diabetologia 7/2009

01-07-2009 | Letter

Causal interpretation requires appropriate study design

Author: P. C. Priest

Published in: Diabetologia | Issue 7/2009

Login to get access

Excerpt

To the Editor: I read with interest the paper by Richardson et al. published in Diabetologia [1]. The paper reports a sort of case–control study, but gives very little information about the age or other demographic or clinical characteristics of the cases and controls, so it is not possible to properly assess the appropriateness of the control group. At the very least, it is unlikely to represent an unbiased sample of the population from which the cases arose (which is not described). For example, would one expect neonates to have had the opportunity to be infected with enterovirus? Presumably not. Therefore, except for neonatal cases (of which there were none), neonates should not be used as controls. …
Literature
1.
go back to reference Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG (2009) The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia doi:10.1007/s00125-009-1276-0 Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG (2009) The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia doi:10.​1007/​s00125-009-1276-0
Metadata
Title
Causal interpretation requires appropriate study design
Author
P. C. Priest
Publication date
01-07-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1346-3

Other articles of this Issue 7/2009

Diabetologia 7/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine